A controlled study of danazol for the treatment of karyotypically normal spontaneous premature ovarian failure
| Autor: | Beverly J. White, Lawrence M. Nelson, Lorene M. Kimzey, James N. Anasti, Ruby Defensor |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class media_common.quotation_subject Urology Spontaneous remission Primary Ovarian Insufficiency Double-Blind Method Reference Values medicine Humans Prospective Studies Ovarian follicle Ovulation media_common Danazol Gynecology Cross-Over Studies business.industry Estrogen Replacement Therapy Ovary Obstetrics and Gynecology Luteinizing Hormone medicine.disease Crossover study Premature ovarian failure medicine.anatomical_structure Reproductive Medicine Estrogen Karyotyping Female Follicle Stimulating Hormone business Progestin medicine.drug |
| Zdroj: | Fertility and Sterility. 62:726-730 |
| ISSN: | 0015-0282 |
| DOI: | 10.1016/s0015-0282(16)56996-9 |
| Popis: | Objective To determine if the immunomodulatory and gonadotropin-suppressing properties of danazol would improve follicle function or ovulation rates in patients with karyotypically normal spontaneous premature ovarian failure. Design Prospective, double-blind, crossover trial. Setting Tertiary care research institution. Interventions Two intervention phases lasting 4months each: one phase during which patients received a standardized estrogen and progestin replacement regimen and one phase during which each patient received a twice daily 400mg oral dose of danazol. Patients Fifty-two patients with karyotypically normal spontaneous premature ovarian failure ranging in age from 21 to 39years. Main Outcome Measures We measured serum E 2 and P levels weekly during the 2months after each intervention. We defined a serum E 2 >50pg/mL (184 pmol/L) as evidence of ovarian follicle function and a P>3.0ng/mL (9.5nmol/L) as evidence for ovulation. Results Of the 46 patients who completed the study, danazol did not significantly enhance ovarian follicle function or the chance of ovulation. Eight patients ovulated after danazol and four patients ovulated after estrogen and progestin. The power to detect a 30% and a 5% ovulation success rate with therapy was 0.80 and 0.90, respectively. Overall, 30 of 46 women (65%) demonstrated ovarian follicle function and 10 women (21%) ovulated. Conclusion We were unable to demonstrate a statistically significant benefit from the immunomodulatory and gonadotropin-suppressing effects of danazol in patients with karyotypically normal spontaneous premature ovarian failure. These patients often have spontaneous remission. Thus, controlled studies are required to determine the effectiveness of treatments for this condition. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|